Welcome to our dedicated page for NutriBand SEC filings (Ticker: NTRBW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NutriBand's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NutriBand's regulatory disclosures and financial reporting.
NutriBand Inc. (NTRB) reported lower revenue but narrower losses for the three and six months ended July 31, 2026. Revenue for the quarter was $437,514 versus $622,452 a year earlier, and six‑month revenue was $870,913 versus $1,289,884, primarily reflecting reduced sales at Pocono Pharmaceuticals after a principal customer moved operations to Asia.
Six‑month net loss improved to $2,122,517 from $3,389,206, helped by lower selling, general and administrative expenses and reduced research and development spending on the AVERSA Fentanyl program. Operating cash outflow fell to $1,148,103, and cash stood at $3,421,615 with working capital of $2,912,335, which management believes is sufficient to support operations for at least one year and alleviates prior going‑concern uncertainty. The company continues to invest in its AVERSA abuse‑deterrent transdermal pipeline and maintains a material weakness in internal control over financial reporting, despite some remediation efforts.
Nutriband Inc. entered into an amended three-year $5,000,000 credit line facility on June 1, 2026. The revolving line replaces a prior $5,000,000 facility that had been scheduled to expire on July 13, 2026 and carries interest at 7% per annum on drawdowns.
The lender cannot convert amounts outstanding under the credit line into common stock, so this financing remains straight debt rather than potential equity dilution. The company states that the facility is intended to provide funding through the FDA approval process and into commercial-scale manufacturing for its patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.
Nutriband Inc. filed an amendment to its annual report for the year ended January 31, 2026 to add a missing exhibit. The company is now including its Policy Relating to Recovery of Erroneously Awarded Compensation, referred to as the executive compensation Clawback Policy, as Exhibit 97.1.
The Clawback Policy was adopted on January 24, 2026 to comply with NASDAQ listing standards and SEC Rule 10D-1 but was omitted from the original 2026 Form 10-K. The amendment states that, aside from reflecting adoption and filing of this policy, it does not modify or update any other disclosures.
Nutriband Inc. filed a current report to share a press release under Regulation FD. The company has selected a commercial worldwide brand name candidate for its lead product, an abuse-deterrent fentanyl transdermal patch built on its AVERSA™ technology, and will submit the name and labeling to the FDA and other regulators for review and approval. The name is also being filed with the U.S. Patent and Trademark Office to secure trademark protection. Nutriband cites a market analysis suggesting its abuse-deterrent fentanyl transdermal system could reach peak annual U.S. sales between $80 million and $200 million, while it continues development for major global markets and highlights AVERSA’s patent coverage across 46 countries.
Nutriband Inc. reported that its Board of Directors approved the immediate termination of the agreement to sell its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The decision was made on February 13, 2026 after the buyer failed to pay required late fees.
The buyer had not closed by the December 31, 2025 contractual closing date and was obligated to pay late fees under the purchase agreement. Nutriband states it received $30,000 in late fees but has not received any further payments since January 21, 2026, prompting the termination.
Nutriband, Inc. held its 2026 Annual Meeting of Stockholders on January 24, 2026, where shareholders elected seven directors to one-year terms and ratified Sadler, Gibb & Associates, LLC as independent auditor for 2025.
Stockholders also approved an amendment to the Articles of Incorporation increasing authorized preferred stock from 10,000,000 to 20,000,000 shares, and supported the advisory “say on pay” vote for executive compensation. In an advisory vote on frequency, shareholders favored holding the say-on-pay vote every one year.
After the meeting, the Board appointed two new directors, Alessandro Puddu, an Italian Chartered Accountant and Statutory Auditor with extensive audit and corporate advisory experience, and Viorica Carlig, a manager in the aircraft services industry with significant management, growth, and regulatory compliance experience and advanced degrees in economics, business, law, and commerce.
Nutriband Inc. reported continued operating losses and liquidity activity for the six months ended July 31, 2025. The company recorded a net loss of $3,416,710 for the six-month period and used $2,650,313 of cash from operations. Total goodwill remained $1,719,535. Inventory was $138,031 (work-in-process $8,061; finished goods $8,042; raw materials $121,477). The company completed an $8,400,000 equity financing on April 19, 2024 and received $5,305,503 from warrant exercises during the six months ended July 31, 2025. A related-party credit line facility of $5,000,000 (originally $2,000,000) is available; advances bear 7% interest and are due March 19, 2026. The company has operating losses since inception and relies on equity sales and debt to fund operations.
Nutriband Inc. reported recent exercises of its outstanding stock options and warrants for the period from February 1 through July 31, 2025. Holders exercised stock options covering 20,055 shares of common stock for a total exercise price of $44,206.
During the same period, holders of the company’s publicly traded warrants (trading under symbol NTRBW) exercised warrants to purchase 47,076 shares of common stock for a total purchase price of $302,699. In addition, private investors exercised warrants to purchase 778,041 shares of common stock, generating a total exercise price of $5,002,804.